Inactive Instrument
Progenics Pharmaceuticals, Inc. Stock
Stocks
US7431871067
Biotechnology & Medical Research
| Manager | Title | Age | Since |
|---|---|---|---|
David Mims
CEO | Chief Executive Officer | 62 | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 6/19/20 | Issuer sale | Director | 56,393 | 0.0651% | ||
| 6/19/20 | Issuer sale | Director | 170,000 | 0.1963% | ||
| 6/19/20 | Issuer sale | Executive/Senior Manager | 389,864 | 0.4502% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | +1.49% | - | - | 355M | |
| -2.01% | -7.86% | +60.74% | +70.97% | 70.44B | |
| +3.84% | -11.02% | +8.59% | +57.43% | 50.31B | |
| +3.35% | +1.42% | +11.85% | +40.01% | 47.51B | |
| +0.51% | +1.51% | +27.96% | +31.43% | 42.91B | |
| +2.70% | -3.66% | +307.41% | +547.01% | 40.39B | |
| +0.69% | -3.44% | +9.52% | +96.59% | 39.69B | |
| +0.06% | -2.02% | +11.25% | +43.27% | 30.59B | |
| -0.04% | -7.99% | +38.51% | +1.59% | 26.8B | |
| -0.39% | -6.92% | -13.60% | -14.40% | 22.36B | |
| Average | +0.88% | -5.11% | +51.36% | +97.10% | 41.22B | |
| Weighted average by Cap. | +0.98% | -4.90% | +54.82% | +102.72% |
Employees
-
